Semaglutide
GLP-1 Receptor Agonist
A glucagon-like peptide-1 (GLP-1) receptor agonist studied for metabolic and glycemic research.
Overview
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It is a 94% homologous analogue of human GLP-1, modified to extend its half-life. Research has extensively studied its effects on glucose metabolism, insulin secretion, appetite regulation, and body weight.
Research Information
Extensive research on semaglutide has demonstrated its ability to stimulate insulin secretion in a glucose-dependent manner, suppress glucagon release, and slow gastric emptying. Studies have shown significant effects on appetite regulation through central nervous system pathways. Research has also explored cardiovascular outcomes.
Research Dosage Reference
Research protocols vary widely. Standard vials contain 2mg or 5mg lyophilized powder. All dosing information is for research reference only.
Related Research
Disclaimer: All information provided is for educational and research purposes only. This is not medical advice. These compounds are not approved for human use. Always consult with qualified professionals before conducting research.